Nearly one in four patients with chronic hepatitis C (HCV) are denied initial approval for a drug therapy that treats the most common strain of the infection, according to a Yale School of Medicine study.The finding, published Aug. 27 in PLOS ONE,...
Even as students took a break from academics, Yale remained as busy as ever this summer. From new faculty appointments to repurposing a miracle arthritis drug to Connecticut’s largest U.S. naturalization ceremony, there was plenty to talk about since...